Spectral AI Secures Significant Funding for Future Growth
Spectral AI, Inc., an innovative artificial intelligence company dedicated to enhancing medical diagnostics in wound care, has successfully priced a $7.6 million offering. This funding aims to provide essential growth capital that will facilitate the ongoing expansion and development of its groundbreaking DeepView System.
Details of the Offering
The offering consists of the issuance of 4,000,000 shares of common stock, along with pre-funded warrants priced at $1.90 per share. The corresponding warrants have an exercise price of $2.51 per share of common stock.
Leadership Perspective
J. Michael DiMaio, MD, serves as the Chairman of the Board at Spectral AI, and he expressed his enthusiasm about securing this institutional funding. He emphasized the importance of this financing in continuing the development and expansion of the DeepView System’s clinical applications, paving the way towards commercial readiness in the upcoming year.
“This funding underscores our commitment to advancing medical technology and supporting our existing BARDA Project BioShield (PBS) initiative,” DiMaio stated. He affirmed the company's dedication to broadening its AI-powered product offerings, which aim to deliver innovative solutions to the medical community worldwide.
About the DeepView System
Spectral AI is focused on revolutionizing wound care management through its DeepView System, which strives to “See the Unknown.” This predictive AI technology is designed to offer healthcare professionals an objective and immediate assessment of a burn wound’s healing potential before any treatment decisions are made.
The DeepView System, which leverages advanced algorithms, is positioned to not only improve patient outcomes but also to reduce the overall costs associated with healthcare. With a clear goal of exceeding current standards of care, this technology promises fast and accurate insights into treatment options.
Strategic Partners and Support
Northland Capital Markets is involved as the exclusive placement agent for this offering, ensuring that Spectral AI has the necessary strategic support to optimize its path forward. Additionally, Reed Smith, LLP acted as counsel, providing legal assistance as the company navigated this new financial venture.
Contact Information for Media and Investors
For those seeking more information regarding Spectral AI or its operations, inquiries can be directed to David Kugelman at Atlanta Capital Partners LLC. He is reachable via toll-free phone at (866) 692-6847 for U.S. and Canada enquiries, or at (404) 281-8556 on mobile and WhatsApp. He can also be contacted through email at dk@atlcp.com.
Frequently Asked Questions
What is the purpose of the $7.6 million funding?
The funding is intended for the continued development and expansion of the DeepView System at Spectral AI, aiming to enhance medical diagnostics in wound care.
Who is the CEO of Spectral AI?
The Chairman of the Board is J. Michael DiMaio, MD, emphasizing the company's mission and growth strategies.
What technology does the DeepView System utilize?
The DeepView System employs predictive AI technology to assess the healing potential of burn wounds quickly and accurately.
Which financial institution facilitated the recent funding offering?
Northland Capital Markets acted as the exclusive placement agent to facilitate the funding offering for Spectral AI.
How can one contact Spectral AI for more information?
Inquiries can be made to David Kugelman via phone or email, as provided in the article.
